Stem Cells International / 2015 / Article / Fig 3

Research Article

Multiple Myeloma Patients at Various Cytogenetic Risks Benefit Differently from Autologous Stem Cell Transplantation as a Consolidation Therapy

Figure 3

Comparison of PFS in the patients of ASCT group and non-ASCT group in the high-risk subgroup. The median PFS was prolonged 18.3 months in ASCT group (30.5 versus 11.2 months, ).